Avenue Therapeutics, Inc. (ATXI) will report its next earnings on 0. The company reported the earnings of $-0.14/Share in the last quarter where the estimated EPS by analysts was $-0.28/share. The difference between the expected and actual EPS was $0.14/share, which represents an Earnings surprise of 50%.
Many analysts are providing their Estimated Earnings analysis for Avenue Therapeutics, Inc. and for the current quarter 2 analysts have projected that the stock could give an Average Earnings estimate of $-0.28/share. These analysts have also projected a Low Estimate of $-0.29/share and a High Estimate of $-0.28/share.
These analysts also forecasted Growth Estimates for the Current Quarter for ATXI to be 23.7%. They are projecting Next Quarter growth of 57.32%. For the next 5 years, Avenue Therapeutics, Inc. is expecting Growth of 34.38% per annum, whereas in the past 5 years the growth was 23.81% per annum.
Some buy side analysts are also providing their Analysis on Avenue Therapeutics, Inc., where 2 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)
The Relative Volume of the company is 1.53 and Average Volume (3 months) is 43.2 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.
The company shows its Return on Assets (ROA) value of -153%. The Return on Equity (ROE) value stands at -214.2%. While it’s Return on Investment (ROI) value is 0%.
While looking at the Stock’s Performance, Avenue Therapeutics, Inc. currently shows a Weekly Performance of -4.55%, where Monthly Performance is 23.53%, Quarterly performance is 85.84%, 6 Months performance is 78.72% and yearly performance percentage is 79.18%. Year to Date performance value (YTD perf) value is 9.37%. The Stock currently has a Weekly Volatility of 6.93% and Monthly Volatility of 6.60%.